The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients
Open accessAbstract
BACKGROUND: Outcomes in patients with chronic myeloid leukemia in blast phase (CML‐BP) are historically dismal. Herein, the authors sought to analyze the characteristics, prognostic factors, and survival outcomes in patients with CML‐BP in the tyrosine kinase inhibitor (TKI) era. METHODS: A total of 477 patients with CML‐BP were treated with a TKI at some point during the course of their CML. Cox proportional hazard models identified characteristics that were predictive of survival. Overall survival and failure‐free survival were assessed. Optimal cutoff points for specific parameters were identified using classification and regression tree (CART) analysis. RESULTS: The median age of the patients was 53 years (range, 16‐84 years) and 64% were male. Approximately 80% of patients initially were diagnosed in the chronic phase of CML at a median of 41 months (range, 0.7‐298 months) before transformation to CML‐BP. De novo CML‐BP occurred in 71 patients. Approximately 72% of patients received TKI therapy before CML‐BP. The initial therapy for CML‐BP included a TKI alone (35%), a TKI with chemotherapy (46%), and non‐TKI therapies (19%). The median overall survival was 12 months and the median failure‐free survival was 5 months. In multivariate analysis, myeloid immunophenotype, prior TKI, age ≥58 years, lactate dehydrogenase level ≥1227 IU/L, platelet count < 102 K/μL, no history of stem cell transplantation, transition to BP from chronic phase/accelerated phase, and the presence of chromosome 15 aberrations predicted for a significantly increased risk of death. Achievement of major hematologic response and/or complete cytogenetic response to first‐line treatment was found to be predictive of better survival. The combination of a TKI with intensive chemotherapy followed by stem cell transplantation appeared to confer the best outcome. CONCLUSIONS: Patients with CML‐BP continue to pose a therapeutic challenge, have dismal outcomes, and require newer treatment approaches. Cancer 2017;123:4391‐402. © 2017 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pietarinen, P. O., Pemovska, T., Kontro, M., Yadav, B., Mpindi, J. P., Andersson, E. I., Majumder, M. M., Kuusanmäki, H., Koskenvesa, P., Kallioniemi, O., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.30 · Cited by 25 · cited 2×
“Prior TKI (yes/no) 343 (72)/134 (28) Transcript type e13a2 182 (41) e14a2 170 (39) e13a2 plus e14a2 74 (17) e1a2 14 (3) Extramedullary disease 128 (27) Isolated extramedullary disease 50 (39) CNS involvement at any point (yes/no) 50 (13)/327 (87) SCT after BP (yes/no) 104 (22)/373 (78) Patients with ABL mutation testi…”
Background
Cited by
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0776-2 · Cited by 1,547
Self-citationStem cell fate in cancer growth, progression and therapy resistance
Lytle, N. K., Barber, A. G., & Reya, T. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0056-x · Cited by 647
Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
Jabbour, E., & Kantarjian, H. (2018) · American Journal of Hematology · doi:10.1002/ajh.25011 · Cited by 413
Self-citationChronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
Jabbour, E., & Kantarjian, H. (2020) · American Journal of Hematology · doi:10.1002/ajh.25792 · Cited by 410
Self-citationChronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring
Jabbour, E., & Kantarjian, H. (2022) · American Journal of Hematology · doi:10.1002/ajh.26642 · Cited by 281
Self-citation
Metadata
- Authors
- Jain, P., Kantarjian, H. M., Ghorab, A., Sasaki, K., Jabbour, E. J., Nogueras Gonzalez, G., Kanagal‐Shamanna, R., Issa, G. C., Garcia‐Manero, G., KC, D., Dellasala, S., Pierce, S., Konopleva, M., Wierda, W. G., Verstovsek, S., Daver, N. G., Kadia, T. M., Borthakur, G., O'Brien, S., Estrov, Z., Ravandi, F., & Cortes, J. E.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2017-07-25
- Volume
- 123
- Issue
- 22
- Pages
- 4391-4402
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2737594272
- Cited by
- 160
- References
- 1
- FWCI
- 8.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.